Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure AwarenessHeart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Oct 5 2020 | Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Industry News In The News Industry Read More Sep 2 2020 | Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Industry News Industry Read More Sep 1 2020 | Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Industry News Industry Read More Jul 30 2020 | Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Industry News Industry Read More Jul 15 2020 | Update on Merck's New Scientific Efforts to Help Combat COVID-19 Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page Next › Last page Last »
Oct 5 2020 | Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Industry News In The News Industry Read More
Sep 2 2020 | Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Industry News Industry Read More
Sep 1 2020 | Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Industry News Industry Read More
Jul 30 2020 | Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Industry News Industry Read More
Jul 15 2020 | Update on Merck's New Scientific Efforts to Help Combat COVID-19 Industry News Industry Read More
